Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.79 |
| ▸ | HTR7 | P34969 | 6/20 | 0.72 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.67 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.58 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.58 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.58 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.58 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.58 |
| ▸ | DRD3 | P35462 | 2/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.58 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.58 |
| ▸ | HTR1A | P08908 | 1/20 | 0.58 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.58 |
| ▸ | DRD1 | P21728 | 1/20 | 0.58 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9725458 | 0.98 | LMNA (0.82) | LMNAHTR7P2RX7HPGDADORA3 | |
| SCHEMBL738001 | 0.98 | LMNA (0.82) | LMNAHTR7P2RX7HPGDADORA3 | |
| SCHEMBL11119055 | 0.90 | LMNA (0.97) | LMNAHTR7P2RX7ADORA3CHRM1 | |
| SCHEMBL30216825 | 0.88 | HTR7 (0.73) | LMNAHTR7P2RX7ADORA3CHRM1 | |
| SCHEMBL739228 | 0.88 | HTR7 (0.73) | LMNAHTR7P2RX7HPGDADORA3 | |
| SCHEMBL11196707 | 0.88 | HTR7 (0.69) | LMNAHTR7P2RX7HPGDADORA3 | |
| Hydrochloric Acid SCHEMBL9725420 | 0.87 | HTR7 (0.71) | LMNAHTR7P2RX7HPGDADORA3 | |
| SCHEMBL11197962 | 0.85 | HTR7 (0.74) | LMNAHTR7P2RX7ADORA3CHRM1 | |
| SCHEMBL8135911 | 0.84 | HTR7 (1.00) | LMNAHTR7P2RX7ADORA3CHRM1 | |
| SCHEMBL5549618 | 0.84 | LMNA (0.61) | LMNAHTR7P2RX7HPGDOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170183313-A1 | BICYCLIC HETEROCYCLES CAPABLE OF MODULATING T-CELL RESPONSES, AND METHODS OF USING SAME | NOGRA PHARMA LTD (IE) | 2017-06-29 | — | — | US | disclosed |
| US-20170183313-A1 | BICYCLIC HETEROCYCLES CAPABLE OF MODULATING T-CELL RESPONSES, AND METHODS OF USING SAME | NOGRA PHARMA LTD (IE) | 2017-06-29 | — | — | US | disclosed |
| US-20150126553-A1 | BICYCLIC HETEROCYCLES CAPABLE OF MODULATING T-CELL RESPONSES, AND METHODS OF USING SAME | NOGRA PHARMA LIMITED (IE) | 2015-05-07 | — | — | US | disclosed |
| US-20150126553-A1 | BICYCLIC HETEROCYCLES CAPABLE OF MODULATING T-CELL RESPONSES, AND METHODS OF USING SAME | NOGRA PHARMA LIMITED (IE) | 2015-05-07 | — | — | US | disclosed |
| US-20090149445-A1 | TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS | COGHLAN MICHAEL JOSEPH | 2009-06-11 | — | — | US | disclosed |
| EP-1519915-B1 | TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS | LILLY CO ELI (US) | 2009-05-27 | — | — | EP | disclosed |
| US-7411072-B2 | Tricyclic steroid hormone nuclear receptor modulators | ELI LILLY AND COMPANY (US) | 2008-08-12 | — | — | US | disclosed |
| US-20060063759-A1 | Tricyclic steroid hormone nuclear receptor modulators | ELI LILLY AND COMPANY | 2006-03-23 | — | — | US | disclosed |
| EP-1519915-A2 | TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-04-06 | — | — | EP | disclosed |
| WO-2004052847-A2 | TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-06-24 | — | — | WO | disclosed |
| US-5162318-A | Which have pulmonary surfactant secretion promoting activity | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1992-11-10 | — | — | US | disclosed |
| EP-0454330-A1 | Benzimidazolinone derivatives | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1991-10-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150126553-A1 | BICYCLIC HETEROCYCLES CAPABLE OF MODULATING T-CELL RESPONSES, AND METHODS OF USING SAME | NFATC1, RORC, ICOS | LMNA 4812/4885HTR7 1298/4885P2RX7 877/4885 |
| US-20090149445-A1 | TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS | NR5A1, NR3C2, NR3C1 | LMNA 2774/4885HTR7 547/4885P2RX7 1830/4885 |
| US-20170183313-A1 | BICYCLIC HETEROCYCLES CAPABLE OF MODULATING T-CELL RESPONSES, AND METHODS OF USING SAME | NFATC1, RORC, ICOS | LMNA 4812/4885HTR7 1283/4885P2RX7 844/4885 |
| US-20060063759-A1 | Tricyclic steroid hormone nuclear receptor modulators | NR5A1, NR3C2, NR3C1 | LMNA 2846/4885HTR7 502/4885P2RX7 1613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.